On 15th of November 2022, in Torun Nasz Lekarz, Medicover ICS entered into a partnership collaboration to be the Prime Site for IQVIA. As of 2017, IQVIA was reported to be one of the world’s largest contract research organizations. IQVIA is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Medicover ICS entered into a partnership collaboration and agreement with IQVIA. The signing of the agreement took place on 15 November 2022 in Nasz Lekarz Medicover in Torun and was attended by MICS representatives and IQVIA representatives. We are thrilled to join forces with a global leader, and we are very honored to be the Prime Site for IQVIA. As of 2017, IQVIA was reported to be one of the world’s largest contract research organizations.
Rainer Metzger, of MICS said:
Today we are delighted to announce our collaboration with IQVIA. We look forward to continuing our discussion with regards to further cooperation in SMO and Patient recruitment area as well as in other areas mentioned during the meeting.
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of $49 Billion as of August 2021.
